Evotec Expands its 2016 Agreement with Bristol-Myers Squibb

 Evotec Expands its 2016 Agreement with Bristol-Myers Squibb

Nosopharm Signs an Agreement with Evotec to Accelerate the Development of Antibiotics


  • Evotec to receive $6M payment from BMS to expand its partnership with the inclusion of additional cell lines
  • In 2016, Evotec signed a 5-year research agreement with Celgene (now a part of BMS) for the identification of therapies based on Evotec’s technology platforms in conjunction with the human iPSC- based platform for multiple neurodegenerative diseases
  •  iPSCs are adult cells genetically reprogrammed to an embryonic stem cell for expressing genes & properties of embryonic stem cells

Click here to read full press release/ article | Ref: Evotec | Image: Behance

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post